SCHEMBL3484796

SCHEMBL3484796

CC(C)(C)OC(=O)C(CCCON)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
POLB P06746 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
GLA P06280 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
NFKB1 P19838 1/20 0.42
APEX1 P27695 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 1/20 0.39
DNMT1 P26358 3/20 0.39
HSD11B1 P28845 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10166834 0.85 ALDH1A1 (0.44) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL10166837 0.83 ALDH1A1 (0.42) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL2194904 0.81 ALDH1A1 (0.43) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL8189261 0.79 SMN1; SMN2 (0.45) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL27774615 0.78 MAPT (0.57) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL17643692 0.78 MAPT (0.57) ALDH1A1POLBKDM4ETP53GLA
SCHEMBL542345 0.77 ALDH1A1 (0.65) ALDH1A1POLBL3MBTL1MAPTGAA
SCHEMBL30613463 0.76 MAPT (0.54) MAPTSMN1; SMN2HTT
SCHEMBL29025643 0.76 MAPT (0.54) MAPTSMN1; SMN2HTT
SCHEMBL26902832 0.76 MAPT (0.54) MAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140274903-A1 USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST NOVO NORDISK HEALTHCARE AG (CH) 2014-09-18 US disclosed
US-20100028939-A1 Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest NOVO NORDISK HEALTHCARE A/G (CH) 2010-02-04 US disclosed
US-20090240028-A1 Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides NOVO NORDISK A/S (DK) 2009-09-24 US disclosed
US-20090215979-A1 Process for the preparation of alkoxyamine functionalized polyethylene glycols NOVO NORDISK A/S (DK) 2009-08-27 US disclosed
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers NOVO NORDISK A/S (DK) 2009-02-05 US disclosed
EP-1850877-B1 PROCESS FOR THE PREPARATION OF ALKOXYAMINE FUNCTIONALISED POLYETHYLENE GLYCOLS NOVO NORDISK AS (DK) 2008-08-27 EP disclosed
US-20080182783-A1 Growth Hormone Conjugates NOVO NORDISK A/S (DK) 2008-07-31 US disclosed
EP-1853321-A2 INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2007-11-14 EP disclosed
EP-1843790-A2 INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2007-10-17 EP disclosed
US-20060198819-A1 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest NOVO NORDISK HEALTHCARE A/G (CH) 2006-09-07 US disclosed
WO-2006087354-A2 INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2006-08-24 WO disclosed
US-20060182714-A1 Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides NOVO NORDISK A/S (DK) 2006-08-17 US disclosed
EP-1688150-A1 Process for the preparation of alkoxyamine functionalised poly ethylene glycols NOVO NORDISK A/S (DK) 2006-08-09 EP disclosed
WO-2006079641-A2 INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060198819-A1 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest GALE, GALNT2, GALNT1 ALDH1A1 244/4885POLB 3070/4885KDM4E 4442/4885
US-20060182714-A1 Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides VIP, PTMS, PDGFA ALDH1A1 4789/4885POLB 2692/4885KDM4E 4609/4885
US-20090240028-A1 Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides VIP, PTMS, PDGFA ALDH1A1 4789/4885POLB 2692/4885KDM4E 4609/4885
US-20140274903-A1 USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST GALE, GALNT2, GALNT1 ALDH1A1 244/4885POLB 3070/4885KDM4E 4442/4885
US-20080182783-A1 Growth Hormone Conjugates GHRHR, GHSR, GHITM ALDH1A1 1553/4885POLB 3125/4885KDM4E 1918/4885
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers INSR, IAPP, IGF1R ALDH1A1 4305/4885POLB 2763/4885KDM4E 4744/4885
US-20100028939-A1 Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest GALE, GALNT2, GALNT1 ALDH1A1 244/4885POLB 3070/4885KDM4E 4442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.